On Feb. 3, 2021, AXIM Biotechnologies announced initiation of clinical trials for ImmunoPass, the Companyﾒs rapid point-of-care test that semi-quantitatively measures levels of neutralizing antibodies to COVID-19. AXIM’s ImmunoPass had shown a significantly better statistical correlation with SARS-Cov-2 neutralization assays than the currently available antibody tests.